Background. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-documented adverse event from treatment with nitrogen-containing bisphosphonates (NBPs). During a preliminary histomorphometric study aimed at assessing the rate of bone remodeling in the jaws of patients with surgically resected BRONJ, we found a defect of bone mineralization (unpublished data). We hypothesized that osteomalacia could be a risk factor for BRONJ in patients taking NBPs. Therefore, we looked for static and dynamic histomorphometric evidence of osteomalacia in biopsies from subjects with and without BRONJ.
INTRODUCTION
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-documented adverse event of treatment with nitrogencontaining bisphosphonates (NBPs) [1] [2] [3] .
Several several risk factors for BRONJ have been identified, including type and cumulative dose of NBP, tooth extraction, and use of dentures [4] . However, its pathogenesis is not fully understood. Suppression of osteoclast-mediated bone remodelling and angiogenesis have been suggested to play a major pathogenetic role in BRONJ [5, 6] .
During a preliminary histomorphometric study aimed at evaluating the rate of bone remodelling in the jaws of patients with surgically resected BRONJ, we found a defect of bone mineralization in all jaws (unpublished data). In agreement with a study reporting a higher frequency of BRONJ in zoledronate-treated patients with persistently low serum calcium and secondary hyperparathyroidism [7] , we hypothesized that osteomalacia could be a risk factor for BRONJ in patients taking NBPs.
Because osteomalacia is essentially a histological diagnosis and may exist in the absence of biochemical and radiological abnormalities [8] , we performed a case-control study to evaluate the static and dynamic histomorphometric evidence of osteomalacia in biopsies from subjects treated with NBP with or without BRONJ.
PATIENTS AND METHODS
A case-control study was performed between July 2007 and July 2009 by enrolling cases and controls from two cohort studies running at the maxillofacial units of Verona and Padova Universities [9, 10] . Patients in the BRONJ group were treated with NBP for a confirmed diagnosis of osteonecrosis of the mandible or maxilla [3] . They were candidates for surgical resection of the diseased jaw or for tooth extraction in the diseased jawbone without signs of BRONJ as a part of a preventive protocol of BRONJ [10] . Patients in the control group were treated with NBP without clinical and radiological signs of BRONJ [3] . They were candidates for tooth extraction as a part of a preventive protocol of BRONJ [10] . Vitamin D supplementation during NBP treatment was a reason for exclusion. The study protocol was approved by the local ethical committee (resolution 1428 -07), and all patients gave written informed consent.
Clinical and Radiological Assessment
NBP usage was recorded in terms of type, dosage, and duration. Images of the oral cavity were taken using a digital camera (Nikon Finepix S1 Pro; Nikon, Tokyo, Japan). All patients underwent panoramic radiography before bone sampling. Cases also underwent spiral computed tomography and magnetic resonance imaging to define surgical resection margins [9] .
Bone Sampling
Patients were given tetracycline hydrochloride, a fluorochrome incorporated at the bone mineralization front, at a standard dose of 500 mg twice daily for 2 days [11] . The same dose was repeated 12 days after the first dose. Surgery and bone sampling were performed from 5 to 7 days after administration of the second dose of tetracycline. In cases, bone sampling was performed on each resection margin to include the entire crosssectional area of the mandible or maxilla [12] . Alternatively, 4-mm width core bone biopsies containing buccal and lingual cortical plates with cancellous bone were obtained from the alveolar process of the nondiseased jaw using a trephine dental drill under saline irrigation. In the control group, 4-mm width core bone biopsies containing buccal and lingual cortical plates with cancellous bone were obtained as described for the BRONJ group.
Bone samples were fixed in 70% ethanol and embedded in methyl-methacrylate resin (Merck 800590; Merck, Darmstadt, Germany). Bone sections were cut with a microtome (Polycut S; Leica Microsystems, Wetzlar, Germany) equipped with a carbide-tungsten blade. Serial sections of 5-m were cut from each specimen and stained with hematoxylin-eosin (HE) for histological examination. Resin-embedded bone blocks were then cut to obtain 8-m sections, which were stained with Goldner's trichrome and mounted on microscope slides for histomorphometric evaluation. Such 8-m sections were obtained from three different levels of methyl-methacrylate block and were separated by a thickness of 250 m. A total of three to five sections from each level were left unstained for the measurement of fluorescent labelling.
Histological Examination
Histological examination was performed using an optical microscope (Leica DFC 280; Leica Microsystems, Wetzlar, Germany). A single experienced pathologist (B.S.), who was blinded to the clinical status of the patients, examined HE sections looking for signs of osteomyelitis and/or osteonecrosis. Bone was considered normal when its architecture was maintained and necrosis and inflammation were absent. Bone samples with findings of osteomyelitis or osteonecrosis were excluded from the analysis because inflammation and necrosis can interfere with bone mineralization [13] .
Histomorphometry
Measurements were performed by a single experienced operator (D.C.L.), who was blinded to the clinical status of the patients. The system for image analysis included an epifluorescent microscope (Leica DM 2500; Leica Microsystems, Wetzlar, Germany), a digital camera (Leica DFC 420 C; Leica Microsystems, Wetzlar, Germany), and a computer equipped with a software for histomorphometric analysis (Bone version 3.5; Explora Nova, La Rochelle, France).
The histomorphometric values employed for analysis are the mean of three measurements obtained to approximate a three-dimensional evaluation. Histomorphometric analysis and reporting were performed following standard guidelines [14] .The full range of static and dynamic parameters of bone remodelling was measured, but only those pertinent to test the study hypothesis are reported in this paper. In particular, the abnormal deposition of unmineralized osteoid associated with an impaired (delayed) mineralization process was calculated using the following parameters: (a) osteoid volume (i.e., the percentage of unmineralized bone inside a given volume of bone); (b) corrected osteoid thickness (i.e., the mean corrected thickness of osteoid seams); and (c) mineralization lag time (i.e., the average time between osteoid formation and its mineralization). An estimate of mineralization lag time per day was obtained by dividing the osteoid thickness by the adjusted apposition rate. The adjusted apposition rate was obtained by multiplying the distance between the two tetracycline labels (divided by the time between the two tetracycline administrations) with the extent of the labeled surfaces averaged over the entire osteoid surface (mineralizing surfaces/osteoid surfaces).
Overall, osteomalacia was diagnosed in the presence of a mineralization lag time Ͼ100 days, a corrected osteoid thickness Ͼ12.5 mm, and an osteoid volume Ͼ10%, according to the internationally accepted histomorphometric definition of osteomalacia [14] . All thickness and depth measurements were corrected for obliquity by multiplying for /4.
Statistical Analysis
Continuous variables are reported as 25th, 50th, and 75th percentiles and minimum and maximum values because of skewed distributions. Categorical variables are given as the number or percentage of patients with the characteristic of interest. Between-group comparisons of continuous variables were performed using the exact Wilcoxon-Mann-Whitney test and those of categorical variables using Fisher's exact test. Exact logistic regression was used to evaluate the association between BRONJ (yes vs. no), mineralization lag time (Ͼ100 vs. Յ100 days), corrected mean osteoid thickness (Ͼ12.5% vs. Յ12.5%), and osteoid volume (Ͼ10% vs. Յ10%).
Odds ratios (OR) and 95% confidence intervals (CI) were calculated before and after correction for sex (0 ϭ female, 1 ϭ male), age (years/10, continuous) and cancer (0 ϭ no, 1 ϭ yes). We adjusted for these factors because they could independently influence bone metabolism and mineralization.
Statistical analysis was performed on one bone specimen for each patient. If two specimens per patient were available, one was randomly chosen for statistical analysis. Even if we used exact logistic regression, the low number of subjects did not allow us to adequately model the possibility that one subject could contribute more than one bone to the analysis (i.e., a problem of correlated observations) [10] . Statistical analysis was performed using Stata 12.0 (Stata, College Station, TX) and StatXact 9 and LogXact 9 (Cytel, Cambridge, MA). Figure 1 describes the enrollment and selection of cases and controls for bone histomorphometry. Of 25 potentially eligible patients, 2 patients were being supplemented with vitamin D and were excluded from the study. The remaining 23 patients underwent bone biopsy. One patient who underwent maxillary resection had histological evidence of osteomyelitis at the margin of bone resection where the biopsy was taken and was not considered further. Thus, 22 patients were left for bone histomorphometry. Of these, 18 had had their jaws resected and 4 patients had an alveolar bone biopsy from the unaffected jaw. Of 25 eligible control subjects, 4 were not included because their bone biopsies showed osteomyelitis. Therefore, 21 controls underwent bone histomorphometry. Table 1 provides the clinical and histomorphometric measurements of the patients. In the BRONJ group, 18 patients were women and 4 were men. In the control group, 13 patients were women and 8 were men. Patients in the BRONJ group were older than control subjects. The cumulative dose of zoledronate but not of pamidronate was higher in the BRONJ group. Table 2 reports the frequency of osteomalacia as detected by bone histomorphometry. Two bone specimens, all without signs of osteomyelitis or osteonecrosis, were available for 14 patients, but only one of them was randomly chosen for statistical analysis. However, the bone specimens not considered for analysis showed signs of osteomalacia on histomorphometry.
RESULTS
In all, 77% of patients with BRONJ had a mineralization lag time Ͼ100 days as compared with 5% of patients without BRONJ. In addition, 64% of patients with BRONJ had corrected osteoid thickness Ͼ12.5% compared with 5% of patients without BRONJ. A total of 45% of patients with BRONJ had osteoid volume Ͼ10% compared with 5% of patients without BRONJ (Fig. 2) .
As determined by exact logistic regression, the odds of having BRONJ were nearly 60 times higher for patients with a mineralization lag time Ͼ100 days than for those without it (OR ϭ 59, 95% CI: 6 -2,977, p Ͻ .001). These odds were still very high after correction for sex, age, and cancer (adjusted OR ϭ 62, 95% CI: 8 -ϱ, p Ͻ .001). Likewise, the odds of having BRONJ were much higher for patients with an osteoid thickness Ͼ12.5% (crude OR ϭ 32, 95% CI: 4 -1,551, p Ͻ .001; adjusted OR ϭ 36, 95% CI: 3-2,657, p Ͻ .001) and for those with an osteoid volume Ͼ10% (crude OR ϭ 16, 95% CI: 2-758, p ϭ .004; adjusted OR ϭ 55, 95% CI: 2-7,423, p ϭ .003).
Control subjects who had been followed up as part of a cohort study did not develop any sign of BRONJ up to 1 year after bone sampling. The four patients who were excluded from the study because of osteomyelitis were all osteomalacic at histo- 
DISCUSSION
NBPs are a mainstay in the treatment of many diseasesespecially metastatic cancer, for which they can have a substantial impact on a patient's quality of life. However, the use of these drugs has been questioned because of their association with BRONJ. BRONJ is most common in patients treated with high-dose intravenous cancer medications [3] ; it also is associated with oral surgical procedures, such as tooth extraction [15] . However, the mechanisms of BRONJ are incompletely understood, so it is difficult to explain why this disease affects only a small number of patients who use bisphosphonates [16] .
Although a cause-effect relationship cannot be inferred from a single case-control study, our results support the association between osteomalacia and BRONJ development in patients treated with NBPs. Osteomalacia is characterized by an impairment of bone mineralization and is commonly caused by a decrease of the serum calcium-phosphate product, which has multiple causes. Bone mineralization defects are best quantified by histomorphometry, but the necessary harvesting of bone cannot be routinely performed. The availability of a sufficient number of bone biopsies to test the study hypothesis is a strength of this study. The fact that patients and control subjects were not strictly comparable in terms of age and type of NBP treatment was due to the limited number of patients that could be enrolled for the study-not only because BRONJ is infrequent but also because jawbone surgery in patients with BRONJ was considered to be unpredictable at the time of the study [17] .
Vitamin D deficiency can lead to osteomalacia in adults [18, 19] . A recent study has found that vitamin D-depleted rats taking zoledronate are at greater risk of developing BRONJ than rats taking zoledronate alone [20] . Thus, it is tempting to speculate that hypovitaminosis D may also be a risk factor for BRONJ in humans because it was strongly associated with osteomalacia in our study. BRONJ is more frequent in patients with cancer than in patients with metabolic bone disease [3] . Also, hypovitaminosis D is common in such patients [21] ; because of the well-known association between vitamin D depletion and osteomalacia, vitamin D deficiency may be an explanation for the high frequency of osteomalacia found in patients with cancer in our study. Routine use of vitamin D and calcium supplements during NBP treatment is currently rec- ommended [19] . However, the use of supplements was not consistently recommended in Italy when our study was performed [22] . This fact helped the recruitment of patients and allowed us to build up a unique study population, in which we could measure the association between osteomalacia and BRONJ.
Our results are at issue with the currently accepted pathogenetic theory of BRONJ, in which the type of NBP, cumulative dosage, and route of administration are considered to be the main risk factors [15, 23] . The risk of BRONJ has been primarily linked with the duration of NBP therapy, with an incidence up to 11% after 4 years of intravenous treatment in patients with cancer [24] . However, other factors may be related to BRONJ development. The recent observation of BRONJ in patients treated with denosumab [25] , a non-bisphosphonate bone resorption inhibitor, suggests that the development of BRONJ is not specific to NBPs but common to drugs inhibiting osteoclast activity. In addition, undiagnosed mineralization defects in patients taking drugs that inhibit osteoclast activity may have a preeminent role in promoting bone necrosis. Our results are in line with this finding because osteomalacia was a strong predictor of BRONJ in NBP users.
The fact that a combination of osteomalacia and NBP treatment may be needed to confer a substantial risk of BRONJ could explain why BRONJ affects only a small portion of NBP users and why some cancer patients may develop BRONJ even after one or few doses of NBP [26] . Also, high-dose NBPs can induce bone mineralization defects [27, 28] . Of course, it is impossible to say whether osteomalacia was caused by or simply associated with NBP treatment in our patients. It should be nonetheless noted that our patients without BRONJ were not osteomalacic. This adds some plausibility to the hypothesis that NBPs affect bone mineralization in patients with established osteomalacia. A recent animal study has shown a negative impact of NBP on bone mineralization after tooth extraction [29] . Overall, the use of NBPs in subjects with a mineralization defect could compromise bone repair after traumatic injuries to the oral cavity and facilitate BRONJ.
In one study, patients treated with zoledronate had a normal bone mineralization and had not developed osteonecrosis after a median follow-up of 2 years [30] . However, they were mostly osteoporotic, received yearly infusions of zoledronate, and were given vitamin D and calcium supplements. It is possible that the combination of NBPs with undiagnosed osteomalacia may increase the risk of BRONJ in patients with cancer. If our hypothesis of a role for osteomalacia in the pathogenesis of BRONJ is correct, the role of NBP in the pathogenesis of BRONJ would be redefined.
CONCLUSION
Osteomalacia is common in patients with BRONJ. This finding may contribute to a better understanding of the pathogenesis of this disease and help in the development of strategies to increase the safety of NBPs. The characteristic double tetracycline labelling of normal bone is shown in a patient without BRONJ. Magnification, ϫ200.
